Xgene Pharmaceutical Inc. is a late-clinical stage, venture capital-backed, international company utilizing their proprietary linker technology to create novel, multimodal, conjugated molecules for treatment of neurological disorders. Current programs are focused on improving the efficacy and tolerability of pain therapeutics.